ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
Kristen H. Schuster(University of Michigan), Hayley S. McLoughlin(University of Michigan)
Cited by 19
Related Papers
Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice
|Annals of Neurology|2018|156
Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3
|Frontiers in Neuroscience|2023|16
ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
|bioRxiv (Cold Spring Harbor Laboratory)|2022|2
Early transcriptomic perturbations highlight the spinal cord as a key pathogenic region in spinocerebellar ataxia type 3
|Frontiers in Cellular Neuroscience|2026|0